NCT05338957 2022-12-01
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
Shanghai Miracogen Inc.
Phase 1/2 Unknown
Shanghai Miracogen Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Tasly Tianjin Biopharmaceutical Co., Ltd.